Review article · 2014 · Open access
Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials
Cancer, 121(11), 1737–1746 · Published 21 October 2014 · DOI 10.1002/cncr.29082
In brief
“Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials” is a 2014 review article by Ursula A. Matulonis and 3 co-authors, published in Cancer. OpenAlex counts 97 citations as of 22 November 2026, which puts it in the top 5% of works published in 2014 by citations. It is open access: the full text is free to read at Cancer.
- Citations
- 97
- Most cited in
- 2024 (13)
- Field-weighted impact
- 0.67
- References
- 54
- Authors
- 4
Abstract
Ovarian cancer patients are usually diagnosed at an advanced stage, experience recurrence after platinum-based chemotherapy, and eventually develop resistance to chemotherapy. Overall survival (OS), which has improved in recent years as more active treatments have been incorporated into patient care, is regarded as the most clinically relevant endpoint in ovarian cancer trials. However, although there remains a significant need for new treatments that prolong OS further without compromising quality of life, it has become increasingly difficult to detect an OS benefit for investigational treatments because of the use of multiple lines of chemotherapy to treat ovarian cancer. Progression-free survival (PFS), which measures the time to disease progression or death, is unaffected by postprogression therapies but does not evaluate the long-term impact of investigational treatments on tumor biology and responses to future therapies. Recent clinical trials of targeted agents in relapsed ovarian cancer have shown improvements in PFS but not OS, and this is possibly reflective of the long postprogression survival (PPS) period associated with this disease. Intermediate endpoints such as the time to second disease progression or death and the time to second subsequent therapy or death may provide supportive evidence for clinically meaningful PFS improvements and may be used to determine whether these improvements persist beyond the first disease progression and throughout subsequent lines of therapy. For clinical trials that have settings with a long PPS duration and/or involve multiple rounds of postprogression therapy, a primary endpoint of PFS supported by intermediate clinical endpoints and OS may provide a more comprehensive approach for evaluating efficacy.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Matulonis, U. A., Oza, A. M., Ho, T. W., & Ledermann, J. A. (2014). Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials. Cancer, 121(11), 1737–1746. https://doi.org/10.1002/cncr.29082
MLA 9
Matulonis, Ursula A., et al. “Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials.” Cancer, vol. 121, no. 11, 2014, pp. 1737–1746. https://doi.org/10.1002/cncr.29082.
Chicago
Matulonis, Ursula A., Amit M. Oza, Tony W. Ho, and Jonathan Andrew Ledermann. 2014. “Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials.” Cancer 121 (11): 1737–1746. https://doi.org/10.1002/cncr.29082.
Harvard
Matulonis, U. A. et al. (2014) ‘Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials’, Cancer, 121(11), pp. 1737–1746. doi:10.1002/cncr.29082.
IEEE
U. A. Matulonis, A. M. Oza, T. W. Ho, and J. A. Ledermann, “Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials,” Cancer, vol. 121, no. 11, pp. 1737–1746, 2014, doi: 10.1002/cncr.29082.
BibTeX
@article{matulonis2014intermediate,
title = {{Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials}},
author = {Matulonis, Ursula A. and Oza, Amit M. and Ho, Tony W. and Ledermann, Jonathan Andrew},
journal = {Cancer},
year = {2014},
volume = {121},
number = {11},
pages = {1737--1746},
doi = {10.1002/cncr.29082},
url = {https://doi.org/10.1002/cncr.29082}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2017 | 6 | |
| 2018 | 5 | |
| 2019 | 11 | |
| 2020 | 11 | |
| 2021 | 8 | |
| 2022 | 10 | |
| 2023 | 9 | |
| 2024 | 13 | |
| 2025 | 6 | |
| 2026 | 6 |
Its field-weighted citation impact is 0.67: it has been cited 0.67 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- ovarian cancer
- progression-free survival
- overall survival
- post-progression survival
- recurrent ovarian cancer
- targeted therapy
- platinum resistance
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Matulonis, U. A., Oza, A. M., Ho, T. W., & Ledermann, J. A. (2014). Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials. Cancer, 121(11), 1737–1746. https://doi.org/10.1002/cncr.29082
How many times has this paper been cited?
97 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Cancer: sign in and open the PDF from this page.
Who wrote this paper?
Ursula A. Matulonis, Amit M. Oza, Tony W. Ho, Jonathan Andrew Ledermann.
What is the DOI of this paper?
10.1002/cncr.29082, permanently at https://doi.org/10.1002/cncr.29082. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.